These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Laine M; Lehtonen L; Nieminen MS Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622 [No Abstract] [Full Text] [Related]
4. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure. Kota B; Prasad AS; Economides C; Singh BN J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950 [TBL] [Abstract][Full Text] [Related]
6. Ca2+ sensitizer superior to catecholamine during myocardial stunning? Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040 [TBL] [Abstract][Full Text] [Related]
7. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Lehtonen LA Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869 [TBL] [Abstract][Full Text] [Related]
8. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Kivikko M; Lehtonen L Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064 [TBL] [Abstract][Full Text] [Related]
9. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656 [TBL] [Abstract][Full Text] [Related]
10. Evidence-based use of levosimendan in different clinical settings. De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Stocker CF; Shekerdemian LS; Nørgaard MA; Brizard CP; Mynard JP; Horton SB; Penny DJ Crit Care Med; 2007 Jan; 35(1):252-9. PubMed ID: 17133188 [TBL] [Abstract][Full Text] [Related]
12. The utility of levosimendan in the treatment of heart failure. Lehtonen L; Põder P Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447 [TBL] [Abstract][Full Text] [Related]
13. Levosimendan: implications for clinicians. McBride BF; White CM J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189 [TBL] [Abstract][Full Text] [Related]
14. A promising new inotrope: levosimendan. Fotbolcu H; Duman D Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619 [TBL] [Abstract][Full Text] [Related]
15. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites. Asif M Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341 [TBL] [Abstract][Full Text] [Related]
16. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure? Erhardt LR Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology of new agents for acute heart failure syndromes. Gheorghiade M; Teerlink JR; Mebazaa A Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825 [TBL] [Abstract][Full Text] [Related]
18. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Earl GL; Fitzpatrick JT Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899 [TBL] [Abstract][Full Text] [Related]
19. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Follath F Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368 [TBL] [Abstract][Full Text] [Related]
20. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Cleland JG; Nikitin N; McGowan J Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]